The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 14, 2017

Filed:

Nov. 08, 2013
Applicant:

Cornell University, Ithaca, NY (US);

Inventors:

Ari Melnick, New York, NY (US);

Hao Wu, Brookline, MA (US);

Assignee:

Cornell University, Ithaca, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4196 (2006.01); A61K 31/426 (2006.01); C12Q 1/37 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4196 (2013.01); A61K 31/426 (2013.01); C12Q 1/37 (2013.01); G01N 2333/96466 (2013.01); G01N 2500/04 (2013.01); G01N 2500/20 (2013.01);
Abstract

MALT1 cleavage activity is linked to the pathogenesis of activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), a chemo-resistant form of DLBCL. We developed a MALT1 activity assay and identified chemically diverse MALT1 inhibitors. A selected lead compound MI-2 featured direct binding to MALT1 and suppression of its protease function. MI-2 concentrated within human ABC-DLBCL cells and irreversibly inhibited cleavage of MALT1 substrates. This was accompanied by suppression of NF-B reporter activity, inhibition of nuclear localization of c-REL and downregulation of NF-B target gene signature. Most notably, MI-2 was non-toxic to mice, and displayed potent and specific activity against ABC-DLBCL cell lines in vitro, and xenotransplanted ABC-DLBCL tumors in vivo. The compound was also effective against primary human non-GCB-DLBCLs ex vivo.


Find Patent Forward Citations

Loading…